Stephen W Duffy

List of Publications by Year
in descending order

264 papers	18,893 citations	14655 66 h-index	13379 130 g-index
273 all docs	273 docs citations	273 times ranked	13534 citing authors

#	Article	IF	Citations
1	A caseâ€“control study to evaluate the impact of the breast screening programme on breast cancer incidence in England. Cancer Medicine, 2023, 12, 1878-1887.	2.8	8
2	Higher Adenoma Detection Rates at Screening Associated With Lower Long-Term Colorectal Cancer Incidence and Mortality. Clinical Gastroenterology and Hepatology, 2022, 20, e148-e167.	4.4	16
3	Selection of eligible participants for screening for lung cancer using primary care data. Thorax, 2022, 77, 882-890.	5.6	13
4	Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC). British Journal of Cancer, 2022, 126, 673-688.	6.4	22
5	All-cause mortality in multi-cancer screening trials. Journal of Medical Screening, 2022, 29, 1-2.	2.3	0
6	Quantifying the duration of the preclinical detectable phase in cancer screening: a systematic review. Epidemiology and Health, 2022, 44, e2022008.	1.9	3
7	Modeling Multicancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 3-4.	2.5	0
8	A Randomized Trial Comparing Breast Cancer Incidence and Interval Cancers after Tomosynthesis Plus Mammography versus Mammography Alone. Radiology, 2022, 303, 256-266.	7.3	29
9	The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation. British Journal of Cancer, 2022, 126, 1355-1361.	6.4	28
10	Recovery of the breast screening programme following pandemic-related delays: Should we focus on round length or uptake?. Journal of Medical Screening, 2022, , 096914132110664.	2.3	1
11	A new approach to breast cancer terminology based on the anatomic site of tumour origin: The importance of radiologic imaging biomarkers. European Journal of Radiology, 2022, 149, 110189.	2.6	17
12	Developing Reporting Guidelines for Social Media Research (RESOME) by Using a Modified Delphi Method: Protocol for Guideline Development. JMIR Research Protocols, 2022, 11, e31739.	1.0	1
13	Problems With the Canadian National Breast Screening Studies. Journal of Breast Imaging, 2022, 4, 120-121.	1.3	3
14	Post-polypectomy surveillance interval and advanced neoplasia detection rates: a multicenter, retrospective cohort study. Endoscopy, 2022, 54, 948-958.	1.8	5
15	Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB. European Journal of Radiology, 2022, 152, 110323.	2.6	10
16	The role of computer-assisted radiographer reporting in lung cancer screening programmes. European Radiology, 2022, , 1.	4.5	0
17	Benefit of biennial faecal occult blood screening on colorectal cancer in England: A population-based case-control study. Journal of the National Cancer Institute, 2022, , .	6.3	1
18	Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study. Health Technology Assessment, 2022, 26, 1-156.	2.8	3

#	Article	IF	Citations
19	Imaging biomarkers of breast cancers originating from the major lactiferous ducts: Ductal adenocarcinoma of the breast, DAB. European Journal of Radiology, 2022, 154, 110394.	2.6	7
20	Early detection of breast cancer rectifies inequality of breast cancer outcomes. Journal of Medical Screening, 2021, 28, 34-38.	2.3	13
21	A case-control study to evaluate the impact of the breast screening programme on mortality in England. British Journal of Cancer, 2021, 124, 736-743.	6.4	14
22	Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. Thorax, 2021, 76, 161-168.	5.6	27
23	Heterogeneity in colorectal cancer incidence among people recommended 3-yearly surveillance post-polypectomy: a validation study. Endoscopy, 2021, 53, 402-410.	1.8	2
24	Retrospective comparison between single reading plus an artificial intelligence algorithm and two-view digital tomosynthesis with double reading in breast screening. Journal of Medical Screening, 2021, 28, 365-368.	2.3	6
25	P22â€...Impact of adenoma detection rates at flexible sigmoidoscopy on long-term colorectal cancer incidence and mortality. , 2021, , .		0
26	Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. British Journal of Cancer, 2021, 124, 1503-1512.	6.4	24
27	Detection of involved margins in breast specimens with X-ray phase-contrast computed tomography. Scientific Reports, 2021, 11, 3663.	3.3	22
28	Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial. Journal of Medical Screening, 2021, 28, 096914132199748.	2.3	0
29	Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. Journal of Medical Screening, 2021, 28, 389-404.	2.3	44
30	Artificial Intelligence Techniques That May Be Applied to Primary Care Data to Facilitate Earlier Diagnosis of Cancer: Systematic Review. Journal of Medical Internet Research, 2021, 23, e23483.	4.3	26
31	Colorectal cancer risk following polypectomy in a multicentre, retrospective, cohort study: an evaluation of the 2020 UK post-polypectomy surveillance guidelines. Gut, 2021, 70, 2307-2320.	12.1	18
32	Impact of changing from a guaiac faecal occult blood test to a faecal immunochemical test in a national screening programme: Results from a pilot study within the national bowel cancer screening programme in England. Journal of Medical Screening, 2021, 28, 096914132110133.	2.3	2
33	Quantitative breast density analysis to predict interval and node-positive cancers in pursuit of improved screening protocols: a caseâ€“control study. British Journal of Cancer, 2021, 125, 884-892.	6.4	7
34	Beneficial Effect of Consecutive Screening Mammography Examinations on Mortality from Breast Cancer: A Prospective Study. Radiology, 2021, 299, 541-547.	7.3	66
35	Psychological Targets for Lung Cancer Screening Uptake: A Prospective Longitudinal Cohort Study. Journal of Thoracic Oncology, 2021, 16, 2016-2028.	1.1	15
36	Mammography Screening and Research Evidence: The Swedish Contribution. Journal of Breast Imaging, 2021, 3, 637-644.	1.3	1

#	Article	IF	Citations
37	Analysis of the baseline performance of five UK lung cancer screening programmes. Lung Cancer, 2021, 161, 136-140.	2.0	29
38	Targeted encouragement of GP consultations for possible cancer symptoms: a randomised controlled trial. British Journal of General Practice, 2021, 71, e339-e346.	1.4	6
39	Faecal immunochemical testing in bowel cancer screening: Estimating outcomes for different diagnostic policies. Journal of Medical Screening, 2021, 28, 277-285.	2.3	5
40	Concurrent participation in screening for cervical, breast, and bowel cancer in England. Journal of Medical Screening, 2020, 27, 9-17.	2.3	14
41	Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients. British Journal of Cancer, 2020, 122, 692-696.	6.4	32
42	Lung Screen Uptake Trial (LSUT): Randomized Controlled Clinical Trial Testing Targeted Invitation Materials. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 965-975.	5.6	77
43	Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems. Cancers, 2020, 12, 1929.	3.7	49
44	First results from five multidisciplinary diagnostic centre (MDC) projects for non-specific but concerning symptoms, possibly indicative of cancer. British Journal of Cancer, 2020, 123, 722-729.	6.4	41
45	Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines. Annals of Internal Medicine, 2020, 172, 46.	3.9	157
46	Lung Screen Uptake Trial: results from a single lung cancer screening round. Thorax, 2020, 75, 908-912.	5.6	13
47	Online patient simulation training to improve clinical reasoning: a feasibility randomised controlled trial. BMC Medical Education, 2020, 20, 245.	2.4	24
48	Precision Science on Incidence and Progression of Early-Detected Small Breast Invasive Cancers by Mammographic Features. Cancers, 2020, 12, 1855.	3.7	2
49	Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancet Oncology, The, 2020, 21, 1165-1172.	10.7	110
50	The Evaluation of Cancer Screening. Medical Clinics of North America, 2020, 104, 939-953.	2.5	8
51	Weekly COVID-19 testing with household quarantine and contact tracing is feasible and would probably end the epidemic. Royal Society Open Science, 2020, 7, 200915.	2.4	35
52	Use of a GP-endorsed non-participant reminder letter to promote uptake of bowel scope screening: A randomised controlled trial in a hard-to-reach population. Preventive Medicine, 2020, 141, 106268.	3.4	1
53	Mammography screening for breast cancerâ€"the UK Age trial â€“ Authors' reply. Lancet Oncology, The, 2020, 21, e510.	10.7	2
54	Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women. Cancer, 2020, 126, 2971-2979.	4.1	175

#	Article	IF	Citations
55	What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). BMC Cancer, 2020, 20, 570.	2.6	37
56	Prevalence, Symptom Burden, and Underdiagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort. Annals of the American Thoracic Society, 2020, 17, 869-878.	3.2	41
57	Errors in determination of net survival: cause-specific and relative survival settings. British Journal of Cancer, 2020, 122, 1094-1101.	6.4	19
58	Long-term colorectal cancer incidence after adenoma removal and the effects of surveillance on incidence: a multicentre, retrospective, cohort study. Gut, 2020, 69, 1645-1658.	12.1	50
59	Mortality Reduction with Low-Dose CT Screening for Lung Cancer. New England Journal of Medicine, 2020, 382, 572-573.	27.0	43
60	Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality. Cancers, 2020, 12, 976.	3.7	72
61	Radiological audit of interval breast cancers: Estimation of tumour growth rates. Breast, 2020, 51, 114-119.	2.2	14
62	Psychological outcomes of low-dose CT lung cancer screening in a multisite demonstration screening pilot: the Lung Screen Uptake Trial (LSUT). Thorax, 2020, 75, 1065-1073.	5.6	14
63	A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A caseâ€“control study. PLoS Medicine, 2020, 17, e1003489.	8.4	33
64	Calculating, Using and Improving Individual Breast Cancer Risk Estimates. , 2020, , 309-324.		1
65	Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT. Health Technology Assessment, 2020, 24, 1-24.	2.8	23
66	Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme. Lung Cancer, 2019, 134, 66-71.	2.0	40
67	Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening. European Journal of Radiology, 2019, 120, 108646.	2.6	15
68	A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer. JAMA Oncology, 2019, 5, 1718.	7.1	91
69	Long-term excess risk of breast cancer after a single breast density measurement. European Journal of Cancer, 2019, 117, 41-47.	2.8	5
70	Imaging Biomarkers as Predictors for Breast Cancer Death. Journal of Oncology, 2019, 2019, 1-12.	1.3	8
71	Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial. Thorax, 2019, 74, 761-767.	5.6	28
72	Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer. Breast, 2019, 45, 70-74.	2.2	0

#	Article	IF	Citations
73	Test sensitivity of mammography and mean sojourn time over 40 years of breast cancer screening in Nijmegen (The Netherlands). Journal of Medical Screening, 2019, 26, 147-153.	2.3	13
74	â€œThey say it's more aggressive in black womenâ€: Biosociality, breast cancer, and becoming a population â€œat riskâ€. Transactions of the Institute of British Geographers, 2019, 44, 509-523.	2.9	4
75	Methods for Development of the European Commission Initiative on Breast Cancer Guidelines. Annals of Internal Medicine, 2019, 171, 273.	3.9	39
76	Impact of a Lung Cancer Screening Information Film on Informed Decision-making: A Randomized Trial. Annals of the American Thoracic Society, 2019, 16, 744-751.	3.2	23
77	Evaluation of cardiovascular risk in a lung cancer screening cohort. Thorax, 2019, 74, 1140-1146.	5.6	50
78	Risk stratification in breast screening: A word of caution. Journal of Medical Screening, 2019, 26, 57-58.	2.3	1
79	The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer, 2019, 125, 515-523.	4.1	151
80	Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study. Gut, 2019, 68, 1642-1652.	12.1	53
81	Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study. Health Technology Assessment, 2019, 23, 1-84.	2.8	91
82	What Proportion of People Who Try One Cigarette Become Daily Smokers? A Meta-Analysis of Representative Surveys. Nicotine and Tobacco Research, 2018, 20, 1427-1433.	2.6	33
83	Low-dose CT for lung cancer screening â€“ Authors' reply. Lancet Oncology, The, 2018, 19, e135-e136.	10.7	3
84	Association between Screening Mammography Recall Rate and Interval Cancers in the UK Breast Cancer Service Screening Program: A Cohort Study. Radiology, 2018, 288, 47-54.	7.3	21
85	The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial. European Radiology, 2018, 28, 226-234.	4.5	21
86	Screening organization and recall rate in a regional breast screening programme. Journal of Medical Screening, 2018, 25, 55-56.	2.3	1
87	Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer. European Journal of Cancer, 2018, 88, 48-56.	2.8	53
88	Effect of Mammography Screening on Mortality by Histological Grade. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 154-157.	2.5	28
89	Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial. Translational Lung Cancer Research, 2018, 7, S114-S116.	2.8	1
90	OTU-029â€...Faecal immunochemical tests (FIT) for surveillance after screening and polypectomy: an accuracy and efficiency study. , 2018, , .		1

#	Article	IF	Citations
91	Association of symptoms and interval breast cancers in the mammography-screening programme: population-based matched cohort study. British Journal of Cancer, 2018, 119, 1428-1435.	6.4	4
92	Reply to â€˜Comment on â€˜Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysisâ€. British Journal of Cancer, 2018, 119, 1444-1444.	6.4	0
93	The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review. BMC Cancer, 2018, 18, 860.	2.6	42
94	Lung cancer CT screening: are we ready to consider screening biennially in a subgroup of low-risk individuals?. Thorax, 2018, 73, 1006-1007.	5.6	6
95	Trends in lung cancer emergency presentation in England, 2006â€“2013: is there a pattern by general practice?. BMC Cancer, 2018, 18, 615.	2.6	4
96	Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis. British Journal of Cancer, 2018, 118, 1559-1570.	6.4	92
97	Use of a GP-endorsed 12 months' reminder letter to promote uptake of bowel scope screening: protocol for a randomised controlled trial in a hard-to-reach population. BMJ Open, 2018, 8, e022263.	1.9	2
98	Evaluation issues in the Swedish Two-County Trial of breast cancer screening: An historical review. Journal of Medical Screening, 2017, 24, 27-33.	2.3	11
99	Initiators and promoters for the occurrence of screen-detected breast cancer and the progression to clinically-detected interval breast cancer. Journal of Epidemiology, 2017, 27, 98-106.	2.4	8
100	Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet, The, 2017, 389, 1299-1311.	13.7	277
101	Optimum low dose CT screening interval for lung cancer: the answer from NELSON?. Thorax, 2017, 72, 6-7.	5.6	10
102	Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncology, The, 2017, 18, 823-834.	10.7	169
103	Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial. Lancet Oncology, The, 2017, 18, 972-980.	10.7	15
104	GP participation in increasing uptake in a national bowel cancer screening programme: the PEARL project. British Journal of Cancer, 2017, 116, 1551-1557.	6.4	27
105	Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality. Evidence-Based Medicine, 2017, 22, 76-76.	0.6	2
106	Does Reader Performance with Digital Breast Tomosynthesis Vary according to Experience with Two-dimensional Mammography?. Radiology, 2017, 283, 371-380.	7.3	24
107	A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women. European Journal of Radiology, 2017, 94, 133-139.	2.6	8
108	Colorectal adenomas, surveillance, and cancer â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e428.	10.7	1

#	Article	IF	Citations
109	Fear, family and the placing of emotion: Black women's responses to a breast cancer awareness intervention. Social Science and Medicine, 2017, 195, 90-96.	3.8	7
110	European position statement on lung cancer screening. Lancet Oncology, The, 2017, 18, e754-e766.	10.7	428
111	Rapid review of evaluation of interventions to improve participation in cancer screening services. Journal of Medical Screening, 2017, 24, 127-145.	2.3	100
112	Reducing the socioeconomic gradient in uptake of the NHS bowel cancer screening Programme using a simplified supplementary information leaflet: a cluster-randomised trial. BMC Cancer, 2017, 17, 543.	2.6	8
113	The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations. Health Technology Assessment, 2017, 21, 1-536.	2.8	23
114	Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trials. Programme Grants for Applied Research, 2017, 5, 1-302.	1.0	1
115	Reducing the Social Gradient in Uptake of the NHS Colorectal Cancer Screening Programme Using a Narrative-Based Information Leaflet: A Cluster-Randomised Trial. Gastroenterology Research and Practice, 2016, 2016, 1-10.	1.5	10
116	Explaining the Better Prognosis of Screening-Exposed Breast Cancers: Influence of Tumor Characteristics and Treatment. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 479-487.	2.5	10
117	Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial. Thorax, 2016, 71, 996-1005.	5.6	74
118	Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model. International Journal of Oncology, 2016, 49, 361-370.	3.3	20
119	Impact of Screening on Breast Cancer Mortalityâ€"Response. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 873-873.	2.5	0
120	Impact of Screening on Breast Cancer Mortality: The UK Program 20 Years On. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 455-462.	2.5	79
121	Implementation planning for lung cancer screening: five major challenges. Lancet Respiratory Medicine,the, 2016, 4, 685-687.	10.7	13
122	Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial. British Journal of Radiology, 2016, 89, 20160301.	2.2	14
123	Updated results of the Gothenburg Trial of Mammographic Screening. Cancer, 2016, 122, 1832-1835.	4.1	24
124	A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening. British Journal of Cancer, 2016, 115, 1479-1486.	6.4	10
125	Is cancer survival associated with cancer symptom awareness and barriers to seeking medical help in England? An ecological study. British Journal of Cancer, 2016, 115, 876-886.	6.4	51
126	Evaluating a DVD promoting breast cancer awareness among black women aged 25â€"50â€…years in East London. Journal of Epidemiology and Community Health, 2016, 70, 678-682.	3.7	4

#	Article	IF	Citations
127	Ovarian cancer screening: UKCTOCS trial. Lancet, The, 2016, 387, 2602.	13.7	8
128	DCIS and invasive interval breast cancer â€“ Author's reply. Lancet Oncology, The, 2016, 17, e88-e89.	10.7	1
129	Response to Hersch etÂal.. Journal of Medical Screening, 2016, 23, 56-56.	2.3	1
130	Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme. Journal of Medical Screening, 2016, 23, 192-202.	2.3	20
131	Effectiveness of timed and non-timed second appointments in improving uptake in breast cancer screening. Journal of Medical Screening, 2016, 23, 160-163.	2.3	12
132	The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and â€˜hard-to-reachâ€™ patients. BMC Cancer, 2016, 16, 281.	2.6	50
133	A randomised trial of the effect of postal reminders on attendance for breast screening. British Journal of Cancer, 2016, 114, 171-176.	6.4	14
134	Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncology, The, 2016, 17, 109-114.	10.7	108
135	CT screening for lung cancer: Is the evidence strong enough?. Lung Cancer, 2016, 91, 29-35.	2.0	34
136	Lung cancer CT screening: is annual screening necessary?. Lancet Oncology, The, 2016, 17, 543-544.	10.7	14
137	Socioeconomic inequalities in breast and cervical screening coverage in England: are we closing the gap?. Journal of Medical Screening, 2016, 23, 98-103.	2.3	69
138	UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax, 2016, 71, 161-170.	5.6	263
139	Effects of evidence-based strategies to reduce the socioeconomic gradient of uptake in the English NHS Bowel Cancer Screening Programme (ASCEND): four cluster-randomised controlled trials. Lancet, The, 2016, 387, 751-759.	13.7	120
140	Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening. British Journal of Cancer, 2016, 114, 321-326.	6.4	35
141	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technology Assessment, 2016, 20, 1-146.	2.8	204
142	Overdiagnosis associated with breast cancer screening: A simulation study to compare lead-time adjustment methods. Cancer Epidemiology, 2015, 39, 1128-1135.	1.9	11
143	Response to Miller etÂal.. Breast Journal, 2015, 21, 459-461.	1.0	2
144	Estimates of over-diagnosis of breast cancer due to population-based mammography screening in South Australia after adjustment for lead time effects. Journal of Medical Screening, 2015, 22, 127-135.	2.3	21

#	Article	IF	Citations
145	Caseâ€“control Studies on the Effectiveness of Breast Cancer Screening. Epidemiology, 2015, 26, 590-596.	2.7	10
146	Variation in cervical and breast cancer screening coverage in England: a cross-sectional analysis to characterise districts with atypical behaviour. BMJ Open, 2015, 5, e007735.	1.9	32
147	Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open, 2015, 5, e008254.	1.9	136
148	Assessing Improvement in Detection of Breast Cancer with Three-dimensional Automated Breast US in Women with Dense Breast Tissue: The SomoInsight Study. Radiology, 2015, 274, 663-673.	7.3	274
149	Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncology, The, 2015, 16, 1123-1132.	10.7	159
150	Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. Clinical Cancer Research, 2015, 21, 3512-3521.	7.0	161
151	Accuracy of Digital Breast Tomosynthesis for Depicting Breast Cancer Subgroups in a UK Retrospective Reading Study (TOMMY Trial). Radiology, 2015, 277, 697-706.	7.3	149
152	Impact of comorbidity on lung cancer mortality - a report from the Liverpool Lung Project. Oncology Letters, 2015, 9, 1902-1906.	1.8	15
153	LLPi: Liverpool Lung Project Risk Prediction Model for Lung Cancer Incidence. Cancer Prevention Research, 2015, 8, 570-575.	1.5	60
154	A note on the design of cancer screening trials. Journal of Medical Screening, 2015, 22, 65-68.	2.3	17
155	Likely effect of adding flexible sigmoidoscopy to the English NHS Bowel Cancer Screening Programme: impact on colorectal cancer cases and deaths. British Journal of Cancer, 2015, 113, 142-149.	6.4	24
156	Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. British Journal of Cancer, 2015, 113, 1086-1093.	6.4	32
157	Informed Decision-Making and Breast Cancer Screening. Journal of Medical Screening, 2015, 22, 165-167.	2.3	13
158	Systematic review of the breast cancer screening trials is error-ridden. Journal of the Royal Society of Medicine, 2015, 108, 430-431.	2.0	1
159	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genetics in Medicine, 2015, 17, 789-795.	2.4	87
160	Insights from the Breast Cancer Screening Trials: How Screening Affects the Natural History of Breast Cancer and Implications for Evaluating Service Screening Programs. Breast Journal, 2015, 21, 13-20.	1.0	134
161	A caseâ€control study to assess the impact of mammographic density on breast cancer risk in women aged 40â€“49 at intermediate familial risk. International Journal of Cancer, 2015, 136, 2378-2387.	5.1	11
162	The TOMMY trial: a comparison of TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme â€“ a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone. Health Technology Assessment, 2015, 19, 1-136.	2.8	146

#	Article	IF	Citations
163	Factors associated with dropout in a lung cancer high-risk cohort - the Liverpool lung project. International Journal of Oncology, 2014, 44, 2146-2152.	3.3	6
164	Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom. British Journal of Cancer, 2014, 110, 1834-1840.	6.4	32
165	Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programme. British Journal of Cancer, 2014, 110, 560-564.	6.4	16
166	Evaluation of a service intervention to improve awareness and uptake of bowel cancer screening in ethnically-diverse areas. British Journal of Cancer, 2014, 111, 1440-1447.	6.4	34
167	Therapeutic Targeting of Integrin Î±vÎ²6 in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	132
168	A telephone reminder intervention to improve breast screening information and access. Public Health, 2014, 128, 1017-1022.	2.9	15
169	An ongoing caseâ€“control study to evaluate the NHS Bowel Cancer Screening Programme. BMC Cancer, 2014, 14, 945.	2.6	1
170	A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer. Annals of Oncology, 2014, 25, 781-791.	1.2	12
171	Trends in aggregate cancer incidence rates in relation to screening and possible overdiagnosis: A word of caution. Journal of Medical Screening, 2014, 21, 24-29.	2.3	13
172	Recent results from the two Canadian Breast Screening Trials. Journal of Medical Screening, 2014, 21, 59-60.	2.3	2
173	The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening. Cancer Prevention Research, 2014, 7, 362-371.	1.5	112
174	MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Research and Treatment, 2014, 145, 663-672.	2.5	133
175	MyLungRisk: a user-friendly, web-based calculator for risk assessment of lung cancer based on the validated Liverpool Lung Project risk prediction model. International Journal of Health Promotion and Education, 2014, 52, 144-152.	0.9	7
176	Breast cancer screening causes more harm than good: No. Journal of Primary Health Care, 2014, 6, 81-2.	0.6	0
177	Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Cancer Research, 2013, 15, R41.	5.0	75
178	An ongoing case-control study to evaluate the NHS breast screening programme. BMC Cancer, 2013, 13, 596.	2.6	7
179	The contribution of risk prediction models to early detection of lung cancer. Journal of Surgical Oncology, 2013, 108, 304-311.	1.7	21
180	Reduction in rate of node metastases with breast screening: consistency of association with tumor size. Breast Cancer Research and Treatment, 2013, 137, 653-663.	2.5	14

#	Article	IF	Citations
181	A randomised trial of weekend and evening breast screening appointments. British Journal of Cancer, 2013, 109, 597-602.	6.4	16
182	Real and artificial controversies in breast cancer screening. Breast Cancer Management, 2013, 2, 519-528.	0.2	36
183	Evaluation of mammographic surveillance services in women aged 40â€“49 years with a moderate family history of breast cancer: a single-arm cohort study. Health Technology Assessment, 2013, 17, vii-xiv, 1-95.	2.8	11
184	The Impact of Mammographic Screening on Breast Cancer Mortality in Europe: A Review of Observational Studies. Journal of Medical Screening, 2012, 19, 14-25.	2.3	348
185	Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A Literature Review. Journal of Medical Screening, 2012, 19, 42-56.	2.3	338
186	Clinical and epidemiological issues in mammographic density. Nature Reviews Clinical Oncology, 2012, 9, 33-40.	27.6	98
187	Overdiagnosis in the population-based service screening programme with mammography for women aged 40 to 49 years in Sweden. Journal of Medical Screening, 2012, 19, 14-19.	2.3	208
188	Long-term benefits of breast screening. Breast Cancer Management, 2012, 1, 31-38.	0.2	27
189	Strategy for power calculation for interactions: Application to a trial of interventions to improve uptake of bowel cancer screening. Contemporary Clinical Trials, 2012, 33, 213-217.	1.8	6
190	UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax, 2011, 66, 308-313.	5.6	190
191	Potential surrogate endpoints in cancer research â€“ some considerations and examples. Pharmaceutical Statistics, 2011, 10, 34-39.	1.3	3
192	Prognosis and pathology of screenâ€detected carcinomas. Cancer, 2011, 117, 1360-1368.	4.1	47
193	Effectiveness of populationâ€based service screening with mammography for women ages 40 to 49 years. Cancer, 2011, 117, 714-722.	4.1	213
194	Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. Cancer Epidemiology, 2011, 35, 139-144.	1.9	4
195	Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades. Radiology, 2011, 260, 658-663.	7.3	638
196	Comparison of discriminatory power and accuracy of three lung cancer risk models. British Journal of Cancer, 2010, 103, 423-429.	6.4	62
197	Effect of Baseline Breast Density on Breast Cancer Incidence, Stage, Mortality, and Screening Parameters: 25-Year Follow-up of a Swedish Mammographic Screening. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1219-1228.	2.5	155
198	Reply to Explaining variations in survival in breast cancer in the Eastern Region of England. Annals of Oncology, 2010, 21, 670.	1.2	0

#	Article	IF	Citations
199	Absolute Numbers of Lives Saved and Overdiagnosis in Breast Cancer Screening, from a Randomized Trial and from the Breast Screening Programme in England. Journal of Medical Screening, 2010, 17, 25-30.	2.3	217
200	Modelling the likely effect of the increase of the upper age limit from 70 to 73 for breast screening in the UK National Programme. Statistical Methods in Medical Research, 2010, 19, 547-555.	1.5	3
201	Cancer mortality in the 50-69 year age group before and after screening. Journal of Medical Screening, 2010, 17, 159-160.	2.3	13
202	Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet, The, 2010, 375, 1624-1633.	13.7	1,483
203	Commentary on 'What is the point: will screening mammography save my life?' by Keen and Keen. BMC Medical Informatics and Decision Making, 2009, 9, 19.	3.0	0
204	Reply: Estimation of lead-time and overdiagnosis in breast cancer screening. British Journal of Cancer, 2009, 100, 220-220.	6.4	2
205	Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. British Journal of Cancer, 2009, 101, 1338-1344.	6.4	77
206	Early detection of second breast cancers improves prognosis in breast cancer survivors. Annals of Oncology, 2009, 20, 1505-1510.	1.2	154
207	Use of lung cancer risk models in planning research and service programs in CT screening for lung cancer. Expert Review of Anticancer Therapy, 2009, 9, 1467-1472.	2.4	9
208	A caseâ€“control study of the impact of the East Anglian breast screening programme on breast cancer mortality. British Journal of Cancer, 2008, 98, 206-209.	6.4	62
209	The LLP risk model: an individual risk prediction model for lung cancer. British Journal of Cancer, 2008, 98, 270-276.	6.4	406
210	Reply: Early onset of breast cancer in British black women. British Journal of Cancer, 2008, 98, 2012-2012.	6.4	3
211	Lung cancer screening: the way forward. British Journal of Cancer, 2008, 99, 557-562.	6.4	50
212	Reply: Early onset of breast cancer in black British women: how reliable are the findings?. British Journal of Cancer, 2008, 99, 988-988.	6.4	1
213	Complexities in the estimation of overdiagnosis in breast cancer screening. British Journal of Cancer, 2008, 99, 1176-1178.	6.4	69
214	Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view. Breast Cancer Research, 2008, 10, R64.	5.0	44
215	Screening opportunity bias in case-control studies of cancer screening. Journal of Applied Statistics, 2008, 35, 537-546.	1.3	8
216	A case-control study to estimate the impact of the icelandic population-based mammography screening program on breast cancer death. Acta Radiologica, 2007, 48, 948-955.	1.1	55

#	Article	IF	Citations
217	Avoiding bias from aggregate measures of exposure. Journal of Epidemiology and Community Health, 2007, 61, 461-463.	3.7	5
218	Screening younger women with a family history of breast cancer â€“ does early detection improve outcome?. European Journal of Cancer, 2006, 42, 1385-1390.	2.8	42
219	Tumor Size and Breast Cancer Detection: What Might Be the Effect of a Less Sensitive Screening Tool Than Mammography?. Breast Journal, 2006, 12, S91-S95.	1.0	34
220	Overdiagnosis, Sojourn Time, and Sensitivity in the Copenhagen Mammography Screening Program. Breast Journal, 2006, 12, 338-342.	1.0	86
221	Family history and risk of lung cancer: age-at-diagnosis in cases and first-degree relatives. British Journal of Cancer, 2006, 95, 1288-1290.	6.4	27
222	Some issues in screening for breast and other cancers. Journal of Medical Screening, 2006, 13 Suppl 1, S28-34.	2.3	0
223	Modelling and analysis of DCIS detection and reduction in invasive carcinoma â€“ a review. Breast Cancer Online: BCO, 2005, 8, .	0.1	0
224	A review of cancer screening evaluation techniques, with some particular examples in breast cancer screening. Journal of the Royal Statistical Society Series A: Statistics in Society, 2005, 168, 657-677.	1.1	9
225	What should the detection rates of cancers be in breast screening programmes?. British Journal of Cancer, 2005, 92, 597-600.	6.4	16
226	Some current issues in breast cancer screening. Journal of Medical Screening, 2005, 12, 128-133.	2.3	15
227	Screening for Breast Cancer. Surgical Oncology Clinics of North America, 2005, 14, 671-697.	1.5	23
228	Overdiagnosis and overtreatment of breast cancer: Overdiagnosis and overtreatment in service screening. Breast Cancer Research, 2005, 7, 266-70.	5.0	49
229	Overdiagnosis and overtreatment of breast cancer: Estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Research, 2005, 7, 258-65.	5.0	150
230	Overdiagnosis in Screening: Is the Increase in Breast Cancer Incidence Rates a Cause for Concern ?. Journal of Medical Screening, 2004, 11, 23-27.	2.3	80
231	Modelling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme. Journal of Medical Screening, 2004, 11, 117-125.	2.3	28
232	A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. Journal of Medical Screening, 2004, 11, 194-198.	2.3	47
233	Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern?. Journal of Medical Screening, 2004, 11, 23-27.	2.3	79
234	A simple model for potential use with a misclassified binary outcome in epidemiology. Journal of Epidemiology and Community Health, 2004, 58, 712-717.	3.7	30

#	Article	IF	Citations
235	Interaction of dense breast patterns with other breast cancer risk factors in a caseâ€“control study. British Journal of Cancer, 2004, 91, 233-236.	6.4	23
236	A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine, 2004, 23, 1111-1130.	1.6	1,052
237	Mammographic tumor features can predict long-term outcomes reliably in women with 1â€“14-mm invasive breast carcinoma. Cancer, 2004, 101, 1745-1759.	4.1	208
238	The randomized trials of breast cancer screening: what have we learned?. Radiologic Clinics of North America, 2004, 42, 793-806.	1.8	316
239	The Gothenburg Breast Screening Trial. Cancer, 2003, 97, 2387-2396.	4.1	216
240	Misclassification in a matched case-control study with variable matching ratio: application to a study of c-erbB-2 overexpression and breast cancer. Statistics in Medicine, 2003, 22, 2459-2468.	1.6	9
241	Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. European Journal of Cancer, 2003, 39, 1746-1754.	2.8	131
242	Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet, The, 2003, 361, 1405-1410.	13.7	611
243	The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. European Journal of Cancer, 2003, 39, 1755-1760.	2.8	85
244	Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. British Journal of Cancer, 2002, 86, 218-221.	6.4	30
245	All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. Journal of Medical Screening, 2002, 9, 159-162.	2.3	71
246	The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer, 2002, 95, 458-469.	4.1	364
247	Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. Journal of the Royal Statistical Society Series C: Applied Statistics, 2002, 51, 235-243.	1.0	70
248	Beyond randomized controlled trials. Cancer, 2001, 91, 1724-1731.	4.1	513
249	Interpretation of the breast screening trials: a commentary on the recent paper by GÃ¸tzsche and Olsen. Breast, 2001, 10, 209-212.	2.2	49
250	A novel method for prediction of long-term outcome of women with T1a, T1b, and 10â€“14 mm invasive breast cancers: a prospective study. Lancet, The, 2000, 355, 429-433.	13.7	129
251	THE SWEDISH TWO-COUNTY TRIAL TWENTY YEARS LATER. Radiologic Clinics of North America, 2000, 38, 625-651.	1.8	409
252	Primary and Adjuvant Therapy, Prognostic Factors and Survival in 1053 Breast Cancers Diagnosed in a Trial of Mammography Screening. Japanese Journal of Clinical Oncology, 1999, 29, 608-616.	1.3	30

#	Article	IF	Citations
253	A mover-stayer mixture of Markov chain models for the assessment of dedifferentiation and tumour progression in breast cancer. Journal of Applied Statistics, 1997, 24, 265-278.	1.3	18
254	The Gothenburg Breast Cancer Screening Trial: Preliminary Results on Breast Cancer Mortality for Women Aged 39-49. Journal of the National Cancer Institute Monographs, 1997, 1997, 53-55.	2.1	67
255	Recent Results From the Swedish Two-County Trial: The Effects of Age, Histologic Type, and Mode of Detection on the Efficacy of Breast Cancer Screening. Journal of the National Cancer Institute Monographs, 1997, 1997, 43-47.	2.1	56
256	Markov Models of Breast Tumor Progression: Some Age-Specific Results. Journal of the National Cancer Institute Monographs, 1997, 1997, 93-97.	2.1	93
257	The Gothenburg breast screening trial. , 1997, 80, 2091-2099.		195
258	Efficacy of breast cancer screening by age. New results swedish two-county trial. Cancer, 1995, 75, 2507-2517.	4.1	526
259	Screening for Breast Cancer in Women Aged under 50: Mode of Detection, Incidence, Fatality, and Histology. Journal of Medical Screening, 1995, 2, 94-98.	2.3	46
260	Development of a scoring system to judge the scientific quality of information from caseâ€control and cohort studies of nutrition and disease. Nutrition and Cancer, 1995, 24, 231-239.	2.0	34
261	Update of the Swedish two-county program of mammographic screening for breast cancer. Radiologic Clinics of North America, 1992, 30, 187-210.	1.8	185
262	Breast screening, prognostic factors and survival â€“ results from the Swedish two county study. British Journal of Cancer, 1991, 64, 1133-1138.	6.4	166
263	The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit.. Journal of Epidemiology and Community Health, 1989, 43, 107-114.	3.7	322
264	Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. European Journal of Cancer & Clinical Oncology, 1987, 23, 959-962.	0.7	61